tiprankstipranks
Advertisement
Advertisement

DE:C43 Stock Latest News

Company AnnouncementsCosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings
3d ago
PremiumCompany Announcements
Cosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend
8d ago
PremiumCompany Announcements
Cosmo to Showcase Real-Time Medical AI Platforms at NVIDIA GTC 2026
1M ago
PremiumCompany Announcements
Cosmo Sets April General Meeting with Name Change and Payout on Agenda
1M ago
PremiumCompany Announcements
Cosmo Pharmaceuticals Lifts Recurring Revenues, Boosts Dividend and Sets Growth Path to 2030
1M ago
PremiumCompany AnnouncementsCosmo teams with Dutch institutions to expand GI Genius AI into Barrett’s esophagus detection
1M ago
Premium
Company Announcements
Cosmo Pharmaceuticals to Court Investors at Major 2026 Healthcare Conferences
2M ago
Premium
Company Announcements
Cosmo Pharmaceuticals Bolsters Institutional Base With Non‑Dilutive Treasury Share Placement
2M ago
Cosmo Pharmaceuticals Sets 9 March 2026 Webcast for 2025 Full-Year Results
PremiumCompany Announcements
Cosmo Pharmaceuticals Sets 9 March 2026 Webcast for 2025 Full-Year Results
3M ago
Cosmo Pharmaceuticals Enters Scale-Up Phase on Strong 2025 Results and AI, Dermatology Pipeline Momentum
PremiumCompany Announcements
Cosmo Pharmaceuticals Enters Scale-Up Phase on Strong 2025 Results and AI, Dermatology Pipeline Momentum
3M ago
Cosmo Pharmaceuticals’ Breezula: A Promising Breakthrough in Hair-Loss Treatment with Significant Market Potential
PremiumRatings
Cosmo Pharmaceuticals’ Breezula: A Promising Breakthrough in Hair-Loss Treatment with Significant Market Potential
4M ago
Cosmo Pharmaceuticals Unveils Breakthrough Results for Male Hair Loss Treatment
PremiumCompany Announcements
Cosmo Pharmaceuticals Unveils Breakthrough Results for Male Hair Loss Treatment
5M ago
Cosmo Pharmaceuticals Expands Global Reach with Winlevi® Approval in Brazil
PremiumCompany AnnouncementsCosmo Pharmaceuticals Expands Global Reach with Winlevi® Approval in Brazil
5M ago
Cosmo Pharmaceuticals Advances in Sustainability with Enhanced ESG Rating and EcoVadis Recognition
Premium
Company Announcements
Cosmo Pharmaceuticals Advances in Sustainability with Enhanced ESG Rating and EcoVadis Recognition
5M ago
Cosmo Pharmaceuticals to Engage Investors at Key Conferences
Premium
Company Announcements
Cosmo Pharmaceuticals to Engage Investors at Key Conferences
5M ago
Cosmo Pharmaceuticals Secures CE Certification for ColonPRO EU, Expanding AI Colonoscopy Platform to Europe
PremiumCompany Announcements
Cosmo Pharmaceuticals Secures CE Certification for ColonPRO EU, Expanding AI Colonoscopy Platform to Europe
6M ago
Cosmo Pharmaceuticals Secures EU Approval for Innovative Acne Treatment Winlevi®
PremiumCompany Announcements
Cosmo Pharmaceuticals Secures EU Approval for Innovative Acne Treatment Winlevi®
6M ago
Cosmo Pharmaceuticals Expands Global Reach with Winlevi® Approval in South Korea
PremiumCompany Announcements
Cosmo Pharmaceuticals Expands Global Reach with Winlevi® Approval in South Korea
6M ago
Cosmo Pharmaceuticals Gains CHMP Approval for Winlevi® in Europe
PremiumCompany Announcements
Cosmo Pharmaceuticals Gains CHMP Approval for Winlevi® in Europe
8M ago
Cosmo Pharmaceuticals Extends Global Supply Agreement with Takeda
PremiumCompany AnnouncementsCosmo Pharmaceuticals Extends Global Supply Agreement with Takeda
8M ago
Cosmo Pharmaceuticals Unaffected by US Tariffs, Maintains Growth Momentum
Premium
Company Announcements
Cosmo Pharmaceuticals Unaffected by US Tariffs, Maintains Growth Momentum
8M ago
Cosmo Pharmaceuticals Boosts 2025 EBITDA Guidance Amid Strong H1 Performance
Premium
Company Announcements
Cosmo Pharmaceuticals Boosts 2025 EBITDA Guidance Amid Strong H1 Performance
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >